Whole follow-up of 1176 patients with progressive pulmonary fibrosis: nerandomilast 9 mg and 18 mg vs placebo gave HRs of 0.78 (95% CI 0.61-1.00) and 0.77 (0.60-0.99) for the key secondary endpoint of exacerbation, respiratory admission or death; death HR 0.51.
RCTn = 1,176
Wijsenbeek et al. Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial